
The U.S. Food and Drug Administration (FDA) has granted approval to Pfizer Inc's drug, Litfulo, for the treatment of severe alopecia areata (AA) in individuals aged 12 and above. Litfulo is the first drug approved for adolescents with this condition, and it will be available in the coming weeks. The approval marks a significant advancement in treating AA, which affects people of all ages.
Like
Save
Share